An AI Designed This Obesity Drug Molecule to Do the Opposite of What Ozempic Does
Insilico Medicine used its generative AI platform Chemistry42 to design ISM1354, a GIPR-blocking obesity drug candidate meant to pair with GLP-1 therapies and preserve muscle mass — showing 75-104% oral bioavailability and an 18-fold plasma exposure edge over a benchmark compound in animal studies.